Novartis has agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical ...
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 ...
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in ...
Novartis (NVS) announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, ...
Novartis to buy Boston-based clinical-stage biopharma company Anthos Therapeutics for up to $3.1 billion: Basel Tuesday, February 11, 2025, 17:45 Hrs [IST] Novartis announced that ...
The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...
Atrial fibrillation outcomes in patients from Asia and non-Asia countries: insights from GARFIELD-AF
Background Differences in the clinical outcomes and level of risk among Asian versus non-Asian patients with atrial ...
Blackstone Life Sciences has sold Anthos Therapeutics to Novartis for up to $3.1 billion. Anthos is a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the ...
The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...
Novartis has agreed to buy Anthos Therapeutics from private equity firm Blackstone for $3.1 billion, adding a drug in ...
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in P ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback